TY - JOUR
T1 - Uveal melanoma metastatic to the liver
T2 - The role of quantitative volumetric contrast-enhanced MR imaging in the assessment of early tumor response after transarterialchemo
AU - Duran, Rafael
AU - Chapiro, Julius
AU - Frangakis, Constantine
AU - Lin, Ming De
AU - Schlachter, Todd R.
AU - Schernthaner, Rüdiger E.
AU - Wang, Zhijun
AU - Savic, Lynn J.
AU - Tacher, Vania
AU - Kamel, Ihab R.
AU - Geschwind, Jean-Francois Francois
N1 - Funding Information:
Support for this work was provided by National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 CA160771 and P30 CA006973 (Philips Research North America, Briarcliff Manor, NY). Disclosure: J.-F.G. is a consultant for Biocompatibles/BTG, Bayer HealthCare, Guerbet, BTG, Threshold, Guerbet/BTG, Philips Healthcare, and Jennerex and the founder and CEO of PreScience Labs, LLC. Grant support: Biocompatibles/BTG, Bayer HealthCare, Philips Medical, BTG, Threshold, Guerbet/BTG, Threshold, Guerbet, Department of Defense, NCI-Eastern Cooperative Oncology Group, and NIH-R01. M. L. is a Philips employee and supported by NIH-R01.
PY - 2014/8
Y1 - 2014/8
N2 - PURPOSE: To determine whether volumetric changes of enhancement as seen on contrast-enhanced magnetic resonance (MR) imaging can help assess early tumor response and predict survival in patients with metastatic uveal melanoma after one session of transarterial chemoembolization (TACE). MATERIALS AND METHODS: Fifteen patients with 59 lesions who underwent MR imaging before and 3 to 4 weeks after the first TACE were retrospectively included. MR analysis evaluated signal intensities, World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), European Association for the Study of the Liver (EASL), modified RECIST (mRECIST), tumor volume [volumetric RECIST (vRECIST)], and volumetric tumor enhancement [quantitative EASL (qEASL)]. qEASL was expressed in cubic centimeters [qEASL (cm3)] and as a percentage of the tumor volume [qEASL (%)]. Paired t test with its exact permutation distribution was used to compare measurements before and after TACE. The Kaplan-Meier method with the log-rank test was used to calculate overall survival for responders and non-responders. RESULTS: In target lesions, mean qEASL (%) decreased from 63.9% to 42.6% (P =.016). No significant changes were observed using the other response criteria. In non-target lesions, mean WHO, RECIST, EASL, mRECIST, vRECIST, and qEASL (cm3) were significantly increased compared to baseline. qEASL (%) remained stable (P=.214).Median overall survival was 5.6 months. qEASL (cm3) was the only parameter that could predict survival based on target lesions (3.6 vs 40.5 months, P b.001) or overall (target and nontarget lesions) response (4.4 vs 40.9 months, P =.001). CONCLUSION: Volumetric tumor enhancement may be used as a surrogate biomarker for survival prediction in patients with uveal melanoma after the first TACE.
AB - PURPOSE: To determine whether volumetric changes of enhancement as seen on contrast-enhanced magnetic resonance (MR) imaging can help assess early tumor response and predict survival in patients with metastatic uveal melanoma after one session of transarterial chemoembolization (TACE). MATERIALS AND METHODS: Fifteen patients with 59 lesions who underwent MR imaging before and 3 to 4 weeks after the first TACE were retrospectively included. MR analysis evaluated signal intensities, World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), European Association for the Study of the Liver (EASL), modified RECIST (mRECIST), tumor volume [volumetric RECIST (vRECIST)], and volumetric tumor enhancement [quantitative EASL (qEASL)]. qEASL was expressed in cubic centimeters [qEASL (cm3)] and as a percentage of the tumor volume [qEASL (%)]. Paired t test with its exact permutation distribution was used to compare measurements before and after TACE. The Kaplan-Meier method with the log-rank test was used to calculate overall survival for responders and non-responders. RESULTS: In target lesions, mean qEASL (%) decreased from 63.9% to 42.6% (P =.016). No significant changes were observed using the other response criteria. In non-target lesions, mean WHO, RECIST, EASL, mRECIST, vRECIST, and qEASL (cm3) were significantly increased compared to baseline. qEASL (%) remained stable (P=.214).Median overall survival was 5.6 months. qEASL (cm3) was the only parameter that could predict survival based on target lesions (3.6 vs 40.5 months, P b.001) or overall (target and nontarget lesions) response (4.4 vs 40.9 months, P =.001). CONCLUSION: Volumetric tumor enhancement may be used as a surrogate biomarker for survival prediction in patients with uveal melanoma after the first TACE.
UR - http://www.scopus.com/inward/record.url?scp=84907353560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907353560&partnerID=8YFLogxK
U2 - 10.1016/j.tranon.2014.05.004
DO - 10.1016/j.tranon.2014.05.004
M3 - Article
C2 - 24953419
AN - SCOPUS:84907353560
SN - 1944-7124
VL - 7
SP - 447
EP - 455
JO - Translational Oncology
JF - Translational Oncology
IS - 4
ER -